-
Mashup Score: 0Tailoring the management of localised colon cancer in Asia - 2 year(s) ago
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with localised colon cancer
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Treatment option for nonsquamous non-small cell lung cancer (nsqNSCLC) with epidermal growth factor receptor mutations (EGFRm) is limited upon progression after tyrosine kinase inhibitors (TKIs). ORIENT-31 is a randomized, double-blind, phase 3 study of sintilimab (sint, anti-PD-1 antibody) with or without IBI305 (bevacizumab biosimilar) plus chemotherapy (chemo) in patients (pts) with EGFRm…
Source: Annals of OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy https://t.co/sA1Wc6BVZ5 #ESMOasiaweek21 #LCSM
-
-
Mashup Score: 4
The multikinase inhibitor C has shown promising clinical activity in combination with immune checkpoint inhibitors, including A, in multiple tumor types. COSMIC-312 (NCT03755791) is evaluating C+A vs S as first-line systemic treatment for aHCC.
Source: Annals of OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial https://t.co/384o4Cw4fQ #ESMOasiaweek21
-
-
Mashup Score: 1YO Lounge Discussions - 2 year(s) ago
Network with peers and colleagues and get inspired by the YO Lounge Discussions.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOasiaweek21: Young Oncologist Lounge Discussion - Vesalius Talk on adapting data from practice-changing studies into your daily practice in Asia. 📌 21 Nov, 17:30 SGT (10:30 CET) 🔗 https://t.co/5nUoXWQ0pW @LoiSher @herbloong @TeresaSAmaral https://t.co/2X2dUxyjB3
-
-
Mashup Score: 3The impact of IMpower 010 and DESTINY-Lung01 in Asia - 2 year(s) ago
Recently presented studies are likely to change clinical practice in Asia, but regulatory and financial issues will shape when and where this happen
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOasiaweek21: IMpower 010 and DESTINY-Lung01 are likely to change clinical practice in Asia - however regulatory and financial issues will shape when and where this happens ➡️ https://t.co/vF9BcTAnq9 #lcsm #lungcancer #NSCLC @TonyMok9 https://t.co/ULI9ss0BAN
-
-
Mashup Score: 2Encouraging results with sintilimab combination therapy in NSCLC - 2 year(s) ago
In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOasiaweek21: Encouraging results w/ sintilimab combo therapy in EGFR-mutated non-squamous #NSCLC. In the first interim analysis of the ORIENT-31 trial, PFS was slightly improved in pts who progressed after EGFR TKI. ➡️ https://t.co/ivK4PMfxKj #lcsm #lungcancer @APassaroMD https://t.co/3q9S6US6gY
-
-
Mashup Score: 0New data for management of hepatocellular carcinoma - 2 year(s) ago
The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOasiaweek21: New data for management of #hepatocellularcarcinoma. The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration ➡️ https://t.co/SUqtUDofiQ #livercancer #cancerresearch https://t.co/w9yzazEbvz
-
-
Mashup Score: 0ESMO Virtual Plenary: November 2021 - 2 year(s) ago
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #ESMOVirtualPlenary, part of the #ESMOasiaweek21, starting today (19/11) at 12:00 CET / 19:00 SGT 👉 Join our experts: register for free https://t.co/oNQb44jDhe #lcsm #NSCLC #lungcancer #lcsm #cancerresearch https://t.co/HfvGqxyran
-
-
Mashup Score: 1ESMO Virtual Plenary: November 2021 - 2 year(s) ago
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Don’t miss the #ESMOVirtualPlenary presenting the latest research in advanced #HCC (COSMIC-312) - 20 Nov. Join this real-time interaction w/ experts, a special edition part of #ESMOasiaweek21 👉 Register for free https://t.co/cl1iGpwV2i @LubelJohn https://t.co/0kx25YmP9s
-
-
Mashup Score: 4Module - 2 year(s) agoSource: asiaweek.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
#ESMOasiaweek21: ESMO Asia Highlights of the Year in #gastrointestinalcancers, #thoraciccancers & #genitourinarycancers. Join us tomorrow (19 Nov) 👉 https://t.co/R21A4Ogz2r #lcsm @FlorianLordick @TonyMok9 @peters_solange @reswong @ravikanesvaran @tompowles1 @AndresC27622123 https://t.co/bOXrllUm89
-
#ESMOasiaweek21: Tailoring the management of localised #coloncancer to the Asian population. Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines https://t.co/pEch4Q9sxr #CRCSM https://t.co/7BJDJEoB8e